Analyst firms · Mizuho · AXSM
Mizuho AXSM price target and rating history
Axsome Therapeutics Inc. (AXSM) · Health Care
Mizuho rates Axsome Therapeutics Inc. (AXSM) Outperform with a $122 price target, as of its latest action on Dec 31, 2024. It has published 3 rating actions on AXSM since August 2021, including 0 upgrades and 0 downgrades. Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.
- Current rating
- Outperform
- Price target
- $122
- Median target, all firms
- $257.50
- Actions on AXSM
- 3
Mizuho price target on AXSM
Every Mizuho rating on AXSM
- Dec 31, 2024
- Sep 7, 2022
- Aug 10, 2021
How other firms rate AXSM
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Buy | $285 | Sep 23, 2026 |
| BMO Capital Markets | Outperform | $310 | Jul 21, 2026 |
| Wolfe Research | Outperform | $230 | Feb 24, 2026 |
| Morgan Stanley | Equal-Weight | $204 | Jan 8, 2026 |
Questions about Mizuho and AXSM
- What is Mizuho's price target for AXSM?
- Mizuho's latest stated price target for Axsome Therapeutics Inc. (AXSM) is $122, from its action on Dec 31, 2024.
- What is Mizuho's rating on AXSM?
- Mizuho rates AXSM Outperform, a bullish rating, as of Dec 31, 2024.
- When did Mizuho last change its view on AXSM?
- On Dec 31, 2024, Mizuho cuts its price target to $122 from $124, keeps Outperform.
- How does Mizuho's AXSM target compare with other analysts?
- Across 4 firms with a AXSM price target in the last 12 months, the median target is $257.50.
More AXSM rating histories
All Mizuho ratingsAXSM news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.